Roberta J. Worthington

TL;DR: Recent developments toward combination therapies for the treatment of multidrug-resistant bacterial infections are described, and the development of adjuvants that either directly target resistance mechanisms such as the inhibition of β-lactamase enzymes, or indirectly target resistance by interfering with bacterial signaling pathways such as two-component systems (TCSs).

TL;DR: This review discuses the numerous approaches that have been applied to the discovery of lead small molecules that mediate biofilm development and highlights the development of small molecule that inhibit and/or disperse bacterial biofilms through non-microbicidal mechanisms.

TL;DR: Small molecule strategies to overcome resistance to β-lactam antibiotics include the development of β- lactamase inhibitors and compounds that interfere with the ability of the bacteria to sense an antibiotic threat and activate their resistance mechanisms.

TL;DR: This work provides a mechanistic explanation for genome-wide association studies that have linked the NPR-C (Npr3) locus with hypertension by demonstrating the importance of CNP/NPR-C signaling in preserving vascular homoeostasis and suggesting that the CNP-C pathway has potential as a disease-modifying therapeutic target for cardiovascular disorders.

TL;DR: Small molecule interference with bacterial communication and signaling pathways, including quorum sensing and two-component signal transduction systems are focused on, focusing firstly on enzymatic approaches to the degradation of extracellular matrix components to effect biofilm dispersal.